Role of nerves in neurofibromatosis type 1-related nervous system tumors
- PMID: 36327093
- DOI: 10.1007/s13402-022-00723-3
Role of nerves in neurofibromatosis type 1-related nervous system tumors
Abstract
Background: Neurofibromatosis type 1 (NF1) is an autosomal dominant genetic disorder that affects nearly 1 in 3000 infants. Neurofibromin inactivation and NF1 gene mutations are involved in various aspects of neuronal function regulation, including neuronal development induction, electrophysiological activity elevation, growth factor expression, and neurotransmitter release. NF1 patients often exhibit a predisposition to tumor development, especially in the nervous system, resulting in the frequent occurrence of peripheral nerve sheath tumors and gliomas. Recent evidence suggests that nerves play a role in the development of multiple tumor types, prompting researchers to investigate the nerve as a vital component in and regulator of the initiation and progression of NF1-related nervous system tumors.
Conclusion: In this review, we summarize existing evidence about the specific effects of NF1 mutation on neurons and emerging research on the role of nerves in neurological tumor development, promising a new set of selective and targeted therapies for NF1-related tumors.
Keywords: Glioma; Nerve; Nervous system tumors; Neurofibromatosis type 1; Peripheral nerve sheath tumor.
© 2022. Springer Nature Switzerland AG.
Similar articles
-
Neurofibromatosis Type 1 and tumorigenesis: molecular mechanisms and therapeutic implications.Neurosurg Focus. 2010 Jan;28(1):E8. doi: 10.3171/2009.11.FOCUS09221. Neurosurg Focus. 2010. PMID: 20043723
-
Clinical characteristics and NF1 gene mutation analysis of three successive generations in three different Indian families with neurofibromatosis type 1 and peripheral nerve sheath tumours.J Clin Neurosci. 2018 Jul;53:62-68. doi: 10.1016/j.jocn.2018.04.006. Epub 2018 Apr 19. J Clin Neurosci. 2018. PMID: 29680440
-
The role of the immune system in neurofibromatosis type 1-associated nervous system tumors.CNS Oncol. 2017 Jan;6(1):45-60. doi: 10.2217/cns-2016-0024. Epub 2016 Dec 21. CNS Oncol. 2017. PMID: 28001089 Free PMC article. Review.
-
Recent advances in neurofibromatosis type 1.Curr Opin Neurol. 2004 Apr;17(2):101-5. doi: 10.1097/00019052-200404000-00004. Curr Opin Neurol. 2004. PMID: 15021234 Review.
-
NF1 deficiency causes Bcl-xL upregulation in Schwann cells derived from neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.Int J Oncol. 2013 Feb;42(2):657-66. doi: 10.3892/ijo.2012.1751. Epub 2012 Dec 24. Int J Oncol. 2013. PMID: 23292448
Cited by
-
RRM2 as a novel prognostic and therapeutic target of NF1-associated MPNST.Cell Oncol (Dordr). 2023 Oct;46(5):1399-1413. doi: 10.1007/s13402-023-00819-4. Epub 2023 Apr 22. Cell Oncol (Dordr). 2023. PMID: 37086345
-
Emerging mechanism and therapeutic potential of neurofibromatosis type 1-related nerve system tumor: Advancing insights into tumor development.Neurooncol Adv. 2025 Feb 16;7(1):vdaf040. doi: 10.1093/noajnl/vdaf040. eCollection 2025 Jan-Dec. Neurooncol Adv. 2025. PMID: 40134850 Free PMC article. Review.
-
[Gene therapy strategies and prospects for neurofibromatosis type 1].Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2024 Jan 15;38(1):1-8. doi: 10.7507/1002-1892.202309071. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2024. PMID: 38225833 Free PMC article. Chinese.
-
Global research trends in cutaneous neurofibromas: A bibliometric analysis from 2003 to 2022.Skin Res Technol. 2024 Feb;30(2):e13595. doi: 10.1111/srt.13595. Skin Res Technol. 2024. PMID: 38279591 Free PMC article.
References
-
- P.J. Cimino, D.H. Gutmann, Neurofibromatosis type 1, Handbook of clinical neurology 148, 799–811 (2018) https://doi.org/10.1016/b978-0-444-64076-5.00051-x
-
- J.M. Friedman, Epidemiology of neurofibromatosis type 1. Am. J. Med. Genet. 89, 1–6 (1999) - DOI
-
- E. Rad, A.R. Tee, Neurofibromatosis type 1: Fundamental insights into cell signalling and cancer. Semin. Cell Dev. Biol. 52, 39–46 (2016). https://doi.org/10.1016/j.semcdb.2016.02.007 - DOI
-
- G.A. Mashour, P.H. Driever, M. Hartmann, S.N. Drissel, T. Zhang, B. Scharf, U. Felderhoff-Müser, S. Sakuma, R.E. Friedrich, R.L. Martuza, V.F. Mautner, A. Kurtz, Circulating growth factor levels are associated with tumorigenesis in neurofibromatosis type 1. Clin. cancer research: official J. Am. Association Cancer Res. 10, 5677–5683 (2004). https://doi.org/10.1158/1078-0432.Ccr-03-0769 - DOI
-
- D.H. Gutmann, R.E. Ferner, R.H. Listernick, B.R. Korf, P.L. Wolters, K.J. Johnson, Neurofibromatosis type 1. Nat. Rev. Dis. Primers 3, 17004 (2017). https://doi.org/10.1038/nrdp.2017.4 - DOI
Publication types
MeSH terms
Substances
Grants and funding
- 19JC1413/Science and Technology Commission of Shanghai Municipality
- shslczdzk00901/Shanghai Municipal Key Clinical Specialty
- SSMU-ZDCX20180700/Innovative research team of high-level local universities in Shanghai
- 82172228/National Natural Science Foundation of China,China
- 82102344/National Natural Science Foundation of China
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous